Public Release: 

Studies show apo A-I Milano gene transfer and antibody therapy cut atherosclerotic plaque

Presentations: American Heart Association Scientific Sessions 2005

Cedars-Sinai Medical Center

LOS ANGELES (Nov. 14, 2005) - Cardiology researchers at Cedars-Sinai Medical Center have found that a single injection of a harmless virus engineered to carry a beneficial, mutant gene enabled animals to manufacture their own supply of the gene's protein product that protects against plaque buildup in blood vessels. As a result, the amount of plaque was significantly reduced, as was an immune reaction that can lead to plaque buildup and rupture, which can cause a blocked artery and heart attack or stroke.

The researchers will present their findings from this and other studies at the American Heart Association Scientific Sessions 2005 Nov. 13 through 16 in Dallas. They are pursuing a variety of approaches to interrupt the complex processes leading to plaque formation and rupture, seeking new ways to treat and even prevent atherosclerosis.

Apolipoprotein A-I (apo A-I) is a protein that becomes part of HDL, or "good" cholesterol. About 25 years ago, a family in northern Italy was found by Italian researchers to have a mutation in the gene responsible for making the protein. The mutant form (apo A-I Milano) appeared to protect its carriers from cardiovascular disease. In 1994, Cedars-Sinai researchers led by Prediman K. Shah, M.D., director of the Division of Cardiology and the Atherosclerosis Research Center, showed for the first time that intravenous injection of a genetically engineered form of the protein markedly reduced arterial plaque buildup in animals fed a high cholesterol diet. A series of subsequent studies in genetically engineered mice conducted in Shah's laboratory confirmed the potent effects of apo A-I Milano protein on prevention and reversal of plaque build-up.

Based on the results of Shah's studies, a clinical trial was conducted in humans with similar results. After five weeks of once-a-week injections, apo A-I Milano significantly shrank plaque in coronary arteries. The protein appeared to actually remove bad cholesterol, even from sites on arteries where plaque had accumulated.

"The initial studies and treatments were based on injection of the apo A-I Milano protein," said Shah. "Now we are using not the protein, but the gene itself. We are putting the gene inside an innocuous virus and injecting the virus so that the body can produce its own supply of apo A-I Milano. One single injection of the gene, carried by the virus, markedly reduces plaque buildup in mice. Advantages of this approach are that we would not need to produce the protein in the laboratory and there would be no need for repeated injections, as there is with the protein. With the animal studies confirming the effectiveness of the gene therapy approach, it may be possible that human trials could begin within several years."

The gene therapy also modulated an immune response that contributes to plaque buildup and rupture. When LDL (bad cholesterol) remains in the bloodstream, it becomes oxidized, which causes the release of a variety of chemicals that damage the blood vessel. In its attempt to repair the injury, the body floods the area with immune system cells called macrophages, which, along with LDL, infiltrate the blood vessel wall.

The result of this injury-repair cycle is the accumulation of plaque - lipids and macrophages covered by a fibrous cap. Plaques with a large lipid core, many inflammatory cells and a thin cap are especially vulnerable to rupture. If a plaque deposit ruptures, debris can block the flow of blood, but the bloodstream also can be blocked by the formation of a blood clot - the immune system's attempt to heal the rupture.

With a growing understanding of the inflammatory processes involved in the development and threat of "vulnerable" plaque, researchers are looking for ways to limit the local immune response, and in animals receiving the apo A-I Milano gene, macrophage immunoreactivity was reduced by 36 percent and 54 percent, compared to two control groups.

A related study to be presented at the AHA meetings confirmed that transfer of the apo A-I Milano gene is more effective than transfer of the normal apo A-I gene in reducing atherosclerosis and plaque inflammation.

Cedars-Sinai researchers, collaborating with researchers from University of Lund in Sweden, will also describe an immunization technique in which antibodies that specifically target oxidized LDL was injected. An earlier study found that the antibody therapy could prevent plaque buildup, but this work documented that pre-existing plaque could be reduced by up to 50 percent in the animal model.

"The present study suggests that antibody treatment has the ability to rapidly and significantly reduce the extent of already present, advanced atherosclerotic lesions," according to the research team. "Positive immunization with antibodies directed against oxidized LDL isotopes might constitute a future fast-acting therapy for patients at high risk for acute cardiovascular events."


The study on viral vector gene transfer was conducted by Xiao-Jun Li, Kuang-Yuh Chyu, Paul Dimayuga, Juliana Yano, Carmel Ferreira, Ang Ji, Lai Wang, Bojan Cercek, and Prediman K. Shah of Cedars-Sinai Medical Center, and Saswati Chatterjee of City of Hope Medical Center. Funding was provided by a National Institutes of Health grant.

The study comparing apo A-I Milano gene transfer with apo A-I was conducted by Prediman K. Shah, Lai Wang, Theresa Pan, Ada Yukht and Behrooz G. Sharifi of Cedars-Sinai Medical Center. Funding was provided by a National Institutes of Health grant.

The study on antibody treatment was conducted by A. Schiopu, J. Nillson and G.N. Fredrikson of Malmo University Hospital in Sweden; B. Jansson and R. Carlsson of BioInvent International AB in Lund, Sweden; and P.K. Shah of the Atherosclerosis Research Center at Cedars-Sinai Medical Center.

Disclosure: Dr. Shah is a co-inventor of gene therapy technologies that use apo A-I Milano in several ways to attempt to prevent atherosclerosis.He, along with Dr. Jan Nilsson of Sweden, is also a co-inventor of antibody treatment of atherosclerosis.

Information on each study is embargoed until the time of presentation.

1. Presentation Sunday, Nov. 13 at 9 a.m.: "Plaque Regression Induced by Human Recombinant Antibodies against OxLDL Epitopes in LDLR-/- Apobec Mice."
2. Presentation, Monday Nov. 14 at 9 a.m.: "One Single I.M. Injection of Recombinant Adeno-associated Virus Encoding Apo A-I Milano Gene Reduces Aortic Atherosclerosis and Modulates the Inflammatory Phenotype of Vein Graft Lesions in ApoE-/- Mice."
3. Presentation Wednesday Nov. 16 at 10:00 a.m.: "Comparative Anti-atherogenic Effects of Macrophage Specific Expression of Apolipoprotein A-I Milano versus Apolipoprotein A-I Wild Type in ApoE/Apo A-I Double Knockout Mice." [Embargoed until 10 a.m. (CST) Nov. 16.]

One of only five hospitals in California whose nurses have been honored with the prestigious Magnet designation, Cedars-Sinai Medical Center is one of the largest nonprofit academic medical centers in the Western United States. For 17 consecutive years, it has been named Los Angeles' most preferred hospital for all health needs in an independent survey of area residents. Cedars-Sinai is internationally renowned for its diagnostic and treatment capabilities and its broad spectrum of programs and services, as well as breakthroughs in biomedical research and superlative medical education. It ranks among the top 10 non-university hospitals in the nation for its research activities and was recently fully accredited by the Association for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP). Additional information is available at

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.